                </a></li></ul></div><p><strong>Figure 3.  <span>Scintigraphic images of tumor-bearing mice 24 hours post-injection with: a) CasKi tumor, E6-specific mAb <sup>188</sup>Re-C1P5 mAb; b) CasKi tumor, control <sup>188</sup>Re-18B7 mAb; c) Hep 3B2.1-7 and A2058 human metastatic melanoma tumors, HBx-specific <sup>188</sup>Re-4H9 mAb.</span></strong></p><span>THISISTHEEND
